<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806438</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R128/2020</org_study_id>
    <nct_id>NCT04806438</nct_id>
  </id_info>
  <brief_title>Airway Nerve Block Versus Nebulization by Lignocaine During Diagnostic Flexible Bronchoscopy Under Moderate Sedation.</brief_title>
  <official_title>Airway Nerve Block Versus Nebulization by Lignocaine During Diagnostic Flexible Bronchoscopy Under Moderate Sedation. A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effectiveness of nebulization versus airway nerve block technique to achieve&#xD;
      upper airway anesthesia for diagnostic fiberoptic bronchoscopy under moderate sedation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomization was done using computer generated tables of random numbers:&#xD;
&#xD;
      Group A (nebulized lignocaine group) as a control group (n = 60) received 5 ml of 10%&#xD;
      lignocaine by air driven jet nebulizer for 20 min .&#xD;
&#xD;
      Group B (nerve block group) (n = 60) received bilateral superior laryngeal nerve block and&#xD;
      trans-tracheal instillation of 4 ml of 2% lignocaine, along with viscous xylocaine gargles&#xD;
      twice.&#xD;
&#xD;
      Patient tolerance was assessed using the Global Tolerance Score, based on a visual analogue&#xD;
      scale ( VAS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 21, 2021</start_date>
  <completion_date type="Anticipated">July 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 21, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Tolerance Score</measure>
    <time_frame>First two hours in the postoperative period</time_frame>
    <description>The Tolerance Score, defined as the arithmetic mean of global tolerance visual analogue score (VAS)and the mean of scores for the 4 specific sensations, was calculated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Group A (nebulized lignocaine group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 5 ml of 10% lignocaine by air driven jet nebulizer for 20 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (nerve block group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive bilateral superior laryngeal nerve block and transtracheal instillation of 4 ml of 2% lignocaine, along with viscous xylocaine gargles twice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group A</intervention_name>
    <description>Patient will receive 5 ml of 10% lignocaine by air driven jet nebulizer for 20 min</description>
    <arm_group_label>Group A (nebulized lignocaine group)</arm_group_label>
    <other_name>Lignocaine nebulizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group B</intervention_name>
    <description>Patients will receive bilateral superior laryngeal nerve block and transtracheal instillation of 4 ml of 2% lignocaine, along with viscous xylocaine gargles twice</description>
    <arm_group_label>Group B (nerve block group)</arm_group_label>
    <other_name>Airway nerve block</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients planned for diagnostic fiberoptic procedures such as broncho-alveolar lavage,&#xD;
             endobronchial or transbronchial biopsies, or brush cytology.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients less than 21yrs old and patients more than 70 yrs old.&#xD;
&#xD;
          -  Severe respiratory failure (pH &lt; 7.35, partial arterial oxygen pressure &lt;55 mmHg&#xD;
             despite supplemental oxygen).&#xD;
&#xD;
          -  Upper airway surgery or radiation, allergy to lidocaine, Propofol or midazolam, or&#xD;
             bleeding disorder.&#xD;
&#xD;
          -  Hemodynamic instable patient or patient decompensated heart failure.&#xD;
&#xD;
          -  Epileptic patients, severe neurological or psychiatric disorder.&#xD;
&#xD;
          -  Patients requiring cryo-biopsy or endobronchial ultrasound because these procedures&#xD;
             are performed under deep sedation including fiberoptic intubation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heba F Abd El-Aziz Toulan, Lecturer</last_name>
    <phone>01221077317</phone>
    <phone_ext>002</phone_ext>
    <email>heba.toulan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samar M Abdel Twab Soliman, Lecturer</last_name>
    <phone>01006236494</phone>
    <phone_ext>002</phone_ext>
    <email>dr_sm.md@hotmail.com</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

